Literature DB >> 11188979

Use of botulinum toxin type A in the treatment of cervical dystonia.

C L Comella1, J Jankovic, M F Brin.   

Abstract

Botulinum toxin is the most neurotoxic substance known, with a specific action at cholinergic synapses. Acting as a zinc endopeptidase, botulinum toxin cleaves specific proteins involved in vesicle fusion, thereby preventing release of acetylcholine. The therapeutic effect of the toxin taken up presynaptically at the neuromuscular junction is to weaken muscle. Botulinum toxin type A (BTX-A) has been shown to be safe and effective in the treatment of cervical dystonia (CD; also known as spasmodic torticollis). In patients with CD, injections of botulinum toxin dampen or eliminate involuntary muscle activity and improve control of neck movement, pain, and range of motion. To successfully use botulinum toxin as a therapeutic modality, targeting the dystonic muscles, injecting a sufficient quantity of toxin and minimizing diffusion into uninvolved muscle collectively provide the best outcome with the fewest adverse reactions. EMG guidance may allow more precise injections. To maintain responsiveness to the toxin over repeated injections, using the lowest dose at the longest dosing interval has been suggested.

Entities:  

Mesh:

Year:  2000        PMID: 11188979

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

1.  Long term effects of intra-articular botulinum toxin A for refractory joint pain.

Authors:  M L Mahowald; J A Singh; D Dykstra
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 2.  Focal dystonia: the role of botulinum toxin.

Authors:  R Tintner; J Jankovic
Journal:  Curr Neurol Neurosci Rep       Date:  2001-07       Impact factor: 5.081

3.  Comparison between (18)F-FDG PET/CT and EMG Mapping for Identifying Dystonic Superficial Muscles in Primary Cervical Dystonia: Preliminary Results.

Authors:  Su Jin Jang; Joon Young Choi; Duk Hyun Sung; Kwang Hong Park; Ji Young Lee; Sook Kyung Cho; Jang Yu; Kyung-Han Lee; Byung-Tae Kim
Journal:  Nucl Med Mol Imaging       Date:  2010-02-26

4.  Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A.

Authors:  Moshe Jakubowski; Peter J McAllister; Zahid H Bajwa; Thomas N Ward; Patty Smith; Rami Burstein
Journal:  Pain       Date:  2006-10-25       Impact factor: 7.926

5.  Botulinum toxin therapy for cervical dystonia: the science of dosing.

Authors:  Virgilio Gerald H Evidente; Eric J Pappert
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2014-11-12

6.  White Matter Changes in Cervical Dystonia Relate to Clinical Effectiveness of Botulinum Toxin Treatment.

Authors:  Anne J Blood; John K Kuster; Jeff L Waugh; Jacob M Levenstein; Trisha J Multhaupt-Buell; Lewis R Sudarsky; Hans C Breiter; Nutan Sharma
Journal:  Front Neurol       Date:  2019-04-04       Impact factor: 4.003

7.  The Multispecialty Toxin: A Literature Review of Botulinum Toxin.

Authors:  Karen Bach; Richard Simman
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-04-06

8.  Diffusion of botulinum toxins.

Authors:  Matthew A Brodsky; David M Swope; David Grimes
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-08-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.